Uppsala, Sweden, April 10, 2019: Biovica has agreed on a collaboration with IBL-America for sales of DiviTum® for the research market in the US. The partnership will further increase the commercial activities for this customer segment on the single largest market for Biovica.
The agreement gives IBL-America non-exclusive rights to sell DiviTum® to pharmaceutical companies, Contract Research Organizations and research institutes in the US. The collaboration will further increase the commercial activities for this customer segment in the US, which is the single largest market for Biovica.
DiviTum® has great potential within many commercial areas. For the research market, it is useful tool for the pharmaceutical and biotech industry for evaluating cell-cycle regulating compounds, CDK inhibitors and endocrine drugs and can be used all the way from cell culture studies to clinical trials for drug approval.
“DiviTum® will give us an excellent opportunity to generate value for our customers. We look forward to working with Biovica and to expand our product portfolio within the oncology research product line”, says Mark Kowal, President/CEO, IBL-America.
“Besides Biovica’s on-going commercialization initiative for the clinical breast cancer market, we also wish to contribute to the development of new improved oncology drugs. Biovica already have customers in the US research market and on-going collaborations with prominent research institutes. The partnership with IBL-America will create excellent opportunities to grow the customer base for the research market in the US”, says Anders Rylander, CEO Biovica.
“We are excited to work with IBL-America, a company with long experience of distributing high quality laboratory research products in the US. IBL-America will become an important partner to increase our presence for the important US research market”, says Pontus Nobréus, Business Development Director Biovica.
For over 20 years, IBL-America has provided high-quality laboratory reagent assays, antibodies and proteins for research and clinical testing in various areas including, but not limited to, autoimmunity, endocrinology, infectious disease, oncology and neuroscience. IBL-America also has the capability to provide technical support with our experienced technical team and their modern, fully-equipped internal laboratory.
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB, email@example.com, +46 8 528 00 399.
Read more: www.biovica.com